Topical ophthalmic medications: What potential for systemic side effects and interactions with other medications?

Medical Journal of Australia

Volumn 189, Issue 7, 2008, Pages 356-357

  Goldberg, Ivan ^a   Moloney, Gregory ^b   McCluskey, Peter ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SYDNEY EYE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHLORAMPHENICOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; COMBIGAN; DORZOLAMIDE PLUS TIMOLOL; FLUOROMETHOLONE; LATANOPROST PLUS TIMOLOL; MONOAMINE OXIDASE INHIBITOR; PROMETHAZINE; PROSTAGLANDIN; SALICYLIC ACID; STEROID; TIMOLOL; TIMOLOL PLUS TRAVOPROST; UNCLASSIFIED DRUG; VERAPAMIL;

ANAMNESIS; BONE MARROW SUPPRESSION; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CONGESTIVE HEART FAILURE; DEPRESSION; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; EDITORIAL; EYEBROW PAIN; FALLING; FLU LIKE SYNDROME; GLAUCOMA; HEALTH HAZARD; HEART RATE; HUMAN; HYPERTENSIVE CRISIS; HYPOTENSION; INFECTION; LAW; MELANCHOLIA; METABOLIC DISORDER; MIOSIS; MYALGIA; MYOPIA; PAIN; PATIENT COUNSELING; PATIENT SAFETY; PRESCRIPTION; RESPIRATORY TRACT DISEASE; RISK FACTOR; SIDE EFFECT; SINUS ARREST; SYSTEMIC DISEASE;

EID: 55449089215     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb02077.x     Document Type: Editorial

References (18)

1. Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002; 240: 430-435.
2. Diggory P, Franks W. Medical treatment of glaucoma - a reappraisal of the risks. Br J Ophthalmol 1996; 80: 85-89.
3. Lewis PR, Phillips TG, Sassani JW. Topical therapies for glaucoma: what family physicians need to know. Am Fam Physician 1999; 59: 1871-1879. http://www.aafp.org/afp/990401ap/1871.html (accessed Aug 2008).
4. Goldberg I, Adena MA. Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clin Experiment Ophthalmol 2007; 35: 700-705.
5. Schuman JS. Effects of systemic β-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology 2000; 107: 1171-1177.
6. Han JA, Frishman WH, Wu Sun S, et al. Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev 2008; 16: 95-108.
7. Gottfredsdottir MS, Allingham RR, Shields MB. Physicians' guide to interactions between glaucoma and systemic medications. J Glaucoma 1997; 6: 377-383.
8. O'Donoghue E. Beta blockers and the elderly with glaucoma: are we adding insult to injury? Br J Ophthalmol 1995; 79: 794-796.
9. Schweitzer I, Maguire K, Ng CH. A case of melancholic depression induced by β-blocker antiglaucoma agents. Med J Aust 2008; 189: 406-407.
10. Glynn RJ, Seddon JM, Krug JH Jr, et al. Falls in elderly patients with glaucoma. Arch Ophthalmol 1991; 109: 205-210.
11. Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Paediatr (Phila) 2004; 43: 99-101.
12. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol 2001; 119: 300-301.
13. Fan DS, Ng JS, Lam DS. A prospective study on ocular hypertensive and antiinflammatory response to different dosages of fluoromethalone in children. Ophthalmology 2001; 108: 1973-1977.
14. Lancaster T, Swart AM, Jick H. Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database. BMJ 1998; 316: 667.
15. Smith JR, Wesselingh S, Coster D. It is time to stop using topical chloramphenicol. Aust N Z J Ophthalmol 1997; 25: 83-88.
16. Lam RF, Lai JSM, Ng JSK, et al. Topical chloramphenicol for eye infections. Hong Kong Med J 2002; 8: 44-47.
17. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 1993; 37: 435-456.
18. Hepsen IF, Yildirim Z, Yilmaz H, Kotuk M. Preventative effect of lacrimal occlusion on topical timolol-induced bronchoconstriction in asthmatics. Clin Experiment Ophthalmol 2004; 32: 597-602.